Pernas, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Pérez-García J, Wach A, Barker D, Fung S, Romagnoli B, Cortés J. The CXCR4 antagonist, balixafortide, plus eribulin in HER2-negative metastatic breast cancer: A phase I, open-label, single-arm trial. Lancet Oncol 2018; 19(6): 812-24